Xenome adds Cherrington to board

Experienced biotech board jockey, Dr Julie Cherrington, has joined the board of the privately listed Xenome as an independent, non-executive director. The appointment was effective as of August 1.

Cherrington has held numerous posts in Australia and the United States in biotechnology companies, including seats on the boards of ChemGenex and Progen Pharmceuticals.

She is also president of San Diego-based biopharmceutical company, Phenomix Corporation. Prior to her appointment as president, Cherrington served as the executive vice president of research and development at Phenomix. She has also held research positions at SUGEN and Gilead Sciences.

Xenome focuses on discovery and development of peptide-based therapeutics derived from venom. Its lead product is Xen2174, a novel conopeptide analogue for the treatment of moderate to severe pain.

Xenome was profiled in the September/October 2008 issue of Australian Life Scientist.